2nd BLOCK Part 2 Flashcards
A 66-year-old man had a myocardial infarct. Which one of the following would be appropriate prophylactic antiarrhythmic therapy?
A. Lidocaine. B. Metoprolol. C. Procainamide. D. Quinidine. E. Verapamil.
Metoprolol
A 58-year-old woman is being treated for chronic suppression of a ventricular arrhythmia. After 2 months of therapy, she complains about feeling tired all the time. Examination reveals a resting heart rate of 10 beats per minute lower than her previous rate. Her skin is cool and clammy. Laboratory test results indicate low thyroxin and elevated thyroid-stimulating hormone levels. Which of the following antiarrhythmic drugs is the likely cause of these signs and symptoms?
A. Amiodarone.
B. Procainamide.
C. Propranolol.
D. Quinidine
Amiodarone
Slow conduction in ischemic and depolarized cells and slow or abolish abnormal pacemakers wherever these processes depend on sodium channels.
GROUP 1 ANTIARRHYTHMICS
LOCAL ANESTHETICS
Slow the rate of rise of the action potential (thus slowing conduction), prolong the action potential, and increase the ventricular effective refractory period
Group A1 Drugs
Can be used in all types of arrhythmias: atrial and ventricular arrhythmias are most responsive and commonly used in arrhythmias during the acute phase of myocardial infarction.
Procainamide
Causes cinchonism (headache, vertigo, tinnitus); cardiac depression; gastrointestinal upset; and autoimmune reactions (eg, thrombocytopenic purpura).
Quinidine
May cause hypotension and a reversible syndrome similar to lupus erythematosus.
Procainamide
May cause hypotension and a reversible syndrome similar to lupus erythematosus.
Procainamide
Is particularly associated with quinidine and other drugs that prolong AP duration
Torsades de pointes
Usually exacerbates the cardiac toxicity of group1 drugs.
Hyperkalemia
An orally active 1B agent.
Mexiletine
Selectively affect ischemic or depolarized Purkinje and ventricular tissue and have little effect on atrial tissue
Group 1B Drugs
Because these agents have little effect on normal cardiac cells, they have little effect on the ECG
Group 1B Drugs
Useful in acute ischemic ventricular arrhythmias, for example, after myocardial infarction.
Lidocaine
Never given orally because it has a very high first-pass effect and its metabolites are potentially cardiotoxic in acute ischemic ventricular arythmias
Lidocaine
These drugs ocasionally cause typical local anesthetic toxicity (ie, central nervous system [CNS] stimulation, including convulsions); cardiovascular depression (usually minor); and allergy (usually rashes but may extend to anaphylaxis) except:
- Lidocaine
- mexiletine
- Quinidine
- Procainamide
Quinidine
Procainamide
Does: Lidocaine and mexiletine
These drugs have no effect on ventricular AP duration or the QT interval and they are powerful depressants of sodium current, however, and can markedly slow conduction velocity in atrial and ventricular cells
Group 1C Drugs
Is approved only for refractory ventricular tachycardias and for certain intractable supraventricular arrhythmias. They are also more likely than other antiarrhythmic drugs to exacerbate or precipitate arrhythmias (proarrhythmic effect).
Flecainide
Is primarily cardiac β-adrenoceptor blockade and reduction in cAMP, which results in the reduction of both sodium and calcium currents and the suppression of abnormal pacemakers.
GROUP 2 ANTIARRHYTHMICS
BETA BLOCKERS